James Gulley, MD
Enriched profileSenior Investigator and Acting Co-Director, Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute · National Cancer Institute
James Gulley is Senior Investigator and Acting Co-Director, Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute at National Cancer Institute. OpenAlex indexes 985 publications with 28,235 citations (h-index 89); ClinicalTrials.gov lists 28 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Hematology / Oncology profiles in the findmyKOL directory.
Data verified 17 Oct 2026
Overview
Updated 18 Oct 2026
James Gulley, MD PHD FACP, is Senior Investigator and Acting Co-Director, Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute. The public record shows 985 publications with 28,235 citations (h-index 89), centered on Cancer Immunotherapy and Biomarkers, Immunotherapy and Immune Responses, Prostate Cancer Treatment and Research. It also documents an investigator role on 28 registered clinical trials, industry payments reported by 2 companies.
- Most recent indexed publication: 2026 · Journal for immunotherapy of cancer
- Top research focus: Cancer Immunotherapy and Biomarkers
- 28 registered trials on ClinicalTrials.gov
- Open Payments reporting from 2 companies
Generated from the cited public record · current as of 18 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 81 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 370.
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 18 Oct 2026
Listed as an investigator on 28 registered studies on ClinicalTrials.gov. The most recent:
- A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing
Sponsor: National Cancer Institute (NCI)
- N-803 Alone or in Combination With BN-Brachyury Vaccine or Bintrafusp Alfa (M7824) for Participants With Castration Resistant Prostate Cancer
Sponsor: National Cancer Institute (NCI)
Industry payments
Updated 18 Oct 2026
2 companies reported payments to CMS in program years 2024–2025. These are public disclosures, not judgments. The latest:
- E.R. Squibb & Sons, L.L.C.Program year202511 payments
- Iovance Biotherapeutics, Inc.Program year20241 payment
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Congress activity
Updated 18 Oct 2026
255 congress contributions (2004–2026) across AACR, ASCO, ASH, ASTRO, ENDO, ESMO, SABCS per OpenAlex. The most recent:
- Abstract 5819: Anti-cancer immune effects of PT-112 monotherapy across two disease indications
AACR Annual Meeting
AACR2025Co-author - Abstract CT205: Updated clinical results, recommended phase 2 dose (RP2D) determination and translational study results for START-001: A phase 1/2 trial of invikafusp alfa, a first-in-class TCR b chain-targeted bispecific antibody in patients with anti-PD(L)1-resistant, antigen-rich solid tumors
AACR Annual Meeting
AACR2025Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 18 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- PARP inhibition combined with a T-cell receptor β chain-directed antibody fusion molecule drives polyclonal antitumor immunity and tumor regression.
Journal for immunotherapy of cancer
Article2026 - BLOCKADE OF TUMOR-INTRINSIC TGF-Β SIGNALING DRIVES HYPERPROGRESSION IN SMALL CELL LUNG CANCER.
Cancer discovery
Article2026 - Phase II study of olaparib and durvalumab in patients with metastatic castration-resistant prostate cancer.
Journal for immunotherapy of cancer
Clinical Trial2026 - The quadruple immunotherapy for colorectal cancer (QuICC) trial for mismatch repair-proficient metastatic colorectal cancer.
The oncologist
Clinical Trial2026
Most-cited works
by citation count (OpenAlex)Network
Updated 18 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 18 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/james-gulley-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - LinkedIn
linkedin.com/in/nciprostatedoc
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - Other
ccr.cancer.gov/genitourinary-malignancies-branch/james-l-gulley
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ccr.cancer.gov ↗ - ResearchGate
researchgate.net/profile/James-Gulley
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗ - X / Twitter
x.com/gulleyj1
Mentions by others
where others cite or feature them- Other
blog.sitcancer.org/2021/12/meet-jitcs-new-deputy-editor-in-chief.html
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →blog.sitcancer.org ↗ - YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗ - LinkedIn
LinkedIn: James Gulley MD PhD FACP - Clinical Director, National Cancer Institute (handle: nciprostatedoc)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 18 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →en.wikipedia.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →irp.nih.gov ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →irp.nih.gov ↗
- Medical Oncology Fellowship
National Cancer Institute
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →en.wikipedia.org ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →sto-online.org ↗
Editorial & leadership roles
journal and society appointments- Founding editor
Clinical/Translational Section, Journal for ImmunoTherapy of Cancer (JITC)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →irp.nih.gov ↗ - Member
Stand Up To Cancer (SU2C) Scientific Advisory Committee
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →standuptocancer.org ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →irp.nih.gov ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →irp.nih.gov ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →irp.nih.gov ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →en.wikipedia.org ↗
Secondary affiliations
appointments beyond the home institution- Director
Medical Oncology Service, Center for Cancer Research, NCI
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →en.wikipedia.org ↗ - Attending physician
Genitourinary Malignancies Clinical Research Section, and Director of the Clinical Trials Group, Laboratory of Tumor Immunology and Biology, NCI
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →globaloncologyacademy.org ↗
Media & interviews
press, podcasts and appearances- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →facs.org ↗
- "James Gulley, MD, PhD: The Architecture of Evidence in Immuno-Oncology"
video interview/podcast
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Kevin Brown, MD
National Cancer Institute
Gregory Reaman, MD
National Cancer Institute
Kevin Conlon, MD
National Cancer Institute
Eric J. Feuer
National Cancer Institute
Howard Scher, MD
Memorial Sloan Kettering Cancer Center
Toni Choueiri, MD
Dana-Farber Cancer Institute
Robert Motzer, MD
Memorial Sloan Kettering Cancer Center
Fred Saad, MD
Centre hospitalier de l'Université de Montréal (CHUM)